Multiple Sclerosis (MS)
An immune-mediated disorder of central-nervous-system myelin causing relapsing or progressive neurological symptoms.
Overview
MS is a chronic inflammatory demyelinating disease of the brain and spinal cord. It typically presents in young adults with relapsing neurological episodes and may evolve to progressive disability. Modern disease-modifying therapies markedly reduce relapses and disability accrual.
Symptoms
- • Optic neuritis — painful loss of vision in one eye
- • Limb weakness, numbness or tingling
- • Spasticity, gait disturbance, tremor
- • Fatigue (often disabling)
- • Bladder, bowel and sexual dysfunction
- • Cognitive and mood changes
Risk factors
- • Age 20–40
- • Female sex (3:1)
- • Northern latitudes
- • EBV infection
- • Family history
- • Smoking
Causes
- • Autoimmune demyelination of CNS
- • Strong association with Epstein–Barr virus infection
- • Genetic susceptibility (HLA-DRB1)
- • Low vitamin D, smoking, obesity in adolescence
🚨 Red flags — seek urgent care
- • Sudden loss of vision
- • Acute paralysis, severe weakness or loss of bladder control — possible severe relapse, seek urgent care
- • Persistent fever in someone on immunosuppressive therapy
When to seek care
- • New or worsening neurological symptoms lasting >24 hours
- • Suspected relapse
- • Side effects from disease-modifying therapy
Diagnosis
- • MRI brain and spinal cord with gadolinium — McDonald criteria
- • CSF analysis for oligoclonal bands
- • Visual evoked potentials in selected cases
- • Exclude mimics: NMOSD, vasculitis, B12 deficiency, infection
Treatment
- • Acute relapse: high-dose IV methylprednisolone
- • Disease-modifying therapy — choice tailored to disease activity (e.g. interferons, glatiramer, dimethyl fumarate, ocrelizumab, natalizumab, cladribine)
- • Symptomatic: spasticity (baclofen), fatigue, bladder management, neuropathic pain
- • Rehabilitation: physiotherapy, occupational therapy, neuropsychology
Prevention
- • Smoking cessation
- • Maintain healthy vitamin D
- • Childhood/adolescent obesity prevention may reduce risk
- • Vaccination before starting immunosuppressive therapy
Complications
- • Progressive disability and mobility loss
- • Bladder, bowel and sexual dysfunction
- • Depression and cognitive impairment
- • Treatment-related infections (PML with natalizumab; reactivation of latent infections)
Prognosis
Modern therapy has substantially improved outlook. Many people on highly effective DMTs remain free of relapses or new MRI lesions; life expectancy is close to normal.
Education & self-care
MS is a treatable lifelong condition. Early diagnosis, effective disease-modifying therapy and multidisciplinary care preserve function and quality of life.
Frequently asked questions
Is MS fatal?
MS itself is rarely fatal; life expectancy is only slightly reduced, mainly due to complications like infections.
Can I have children with MS?
Yes. Pregnancy is generally safe; some DMTs need to be stopped beforehand — plan with your neurologist.
Is MS always disabling?
Outcomes vary widely. Modern disease-modifying therapies started early have dramatically reduced relapse rate and long-term disability, especially in relapsing-remitting MS.
Can I exercise and work?
Yes — exercise is positively beneficial and most people remain in work for years. Fatigue management, heat avoidance and workplace adjustments help maintain function.
Is MS inherited?
MS is not directly inherited but there is a small familial component. The risk in a first-degree relative is about 2–3%, compared with 0.1–0.3% in the general population.